Wednesday, November 18, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > CEO Life > The risks and challenges of the global COVID-19-vaccine rollout

The risks and challenges of the global COVID-19-vaccine rollout

in CEO Life, PrimeZone
Share on LinkedinShare on WhatsApp

A realistic assessment of the heroic effort to administer billions of doses of COVD-19 vaccines to an agonized global population is necessary. The stakes could not be higher, says McKinsey.

The COVID-19 vaccines of the BioNTech and Pfizer partnership (Pfizer–BioNTech) and Moderna have received Emergency Use Authorization in Canada, the European Union, the United Kingdom, the United States, and other countries. Many frontline workers and priority population segments have received their first doses. Vaccines from AstraZeneca, Johnson & Johnson, and several other global manufacturers also are arriving and being distributed for administration around the world. This monumental global effort has shattered the record for vaccine development: the fastest previous vaccine project, Merck’s mumps vaccine, was four and a half years in development (1963–67).

In certain places, the COVID-19-vaccine effort has hit a few speed bumps; stockpiles have accumulated, and deployment to vulnerable countries and at-risk groups has been slower than expected. Nonetheless, experts have expressed confidence that safe and highly efficacious vaccines are reaching the market, and we are beginning to see “the light at the end of the tunnel” of this devastating pandemic. The epidemiological end to the COVID-19 pandemic seemed like an optimistic dream a few short months ago, but, with the development, approval, and rollout of several vaccines, it is now practically realizable in much of the world.

To arrive at the postpandemic era, in which populations experience herd immunity, vast numbers of dedicated individuals will need to continue working intensely in the months and years ahead. In this article, we consider elements of this enormous undertaking, the risks that are inherent, and potential means of further accelerating vaccination.

A common operating model of COVID-19-vaccine delivery, shown in the interactive, demonstrates the complexity of the task at hand. Essentially, the interactive is a qualitative risk map, showing the many stages of vaccine deployment and highlighting areas of potential failure as one party interacts with another. A breakdown at any point in the deployment process can set off a cascade, shutting down the entire system.

In the United States alone, hundreds of organizations play a role in vaccine deployment, adapting their operations to meet demands for volume, speed, and better technology. Suppliers, manufacturers, and regulators are collaborating to ramp up production of vaccines. Massive volumes handled, distributed, and stored through cold chains must adhere to safety regulations. Tens of thousands of transporters, vaccine handlers, medical and pharmacy staff, and frontline workers have required training on the specific characteristics of each manufacturer’s distinct vaccines.

At the receiving end, vulnerable populations—especially in developing countries—could face added hurdles, including difficulty in reaching administrative sites, getting time off from work to receive doses, and arranging childcare for the same. Historical wariness of interacting with authorities can also be a barrier. A further issue is vaccine skepticism, affecting a certain segment of all populations, including the United States.

In the United States and other countries with sufficient vaccine quantities and adoption, herd immunity by October 2021 is conceivable, but for that to happen, more than twice as many doses of COVID-19 vaccines will have to be administered each month as were administered during the 2009 H1N1 flu vaccine drive. Cumulatively, between 2.4 and 2.7 times as many doses (mainly because of the double-dose requirement) will be needed as are used for the annual flu vaccinations (exhibit).

Scientists, doctors, other healthcare workers, clinical-trial participants, and regulators have been working intensely to develop, distribute, and administer the vaccines that will help end this pandemic. Their often-heroic efforts give cause for hope. An array of complex challenges are still before us, as production is ramped up and rollouts are planned and executed. A realistic risk assessment of vaccine deployment is needed, because future success cannot be taken for granted. Much needs to be done for the promise of COVID-19 vaccines to become a reality.

Critical emerging risks

The common operating model provides the details of end-to-end vaccine deployment. From this model, we have highlighted six possible areas of risk to the rapid delivery of COVID-19 vaccines in the United States and elsewhere. In a later section, we outline possible approaches to mitigating each of these risks, with practical steps for organizations that have a role in vaccine deployment.

Read the full article at https://www.mckinsey.com/business-functions/risk/our-insights/the-risks-and-challenges-of-the-global-covid-19-vaccine-rollout

This article is a collaborative effort by the global Risk Practice and authors from across the firm, including Gaurav Agrawal, Tara Azimi, Jennifer Heller, Pooja Kumar, Mihir Mysore, Parag Patel, Adam Sabow, Shubham Singhal, and Joseph Truesdale.

Tags: COVID-19RiskVaccinationVaccine

Related Posts

Amazon CEO’s annual letter expresses excitement about AI
Environment

Amazon to invest $7 billion in renewable energy in India

Travel

Yes, the Great Barrier Reef is still a must-see

To be successful in 2025, a therapist says do these 5 things: It works ‘any time of year’
Health

Why switching off from work is so hard

The hidden meanings in Hokusai’s iconic Great Wave
Art & Culture

The hidden meanings in Hokusai’s iconic Great Wave

Smart manufacturing is sustainable manufacturing
Environment

Smart manufacturing is sustainable manufacturing

Not enough STEM women for green jobs: IMF
Environment

Young people are reimagining climate-resilient cities

The friction-free design principles at the heart of Japan’s busiest cities
Art & Culture

The friction-free design principles at the heart of Japan’s busiest cities

Spain’s secret art island
Travel

Spain’s secret art island

How to Fall Asleep in 10, 60, or 120 Seconds
Health

How to Fall Asleep in 10, 60, or 120 Seconds

Emission taxes may undermine corporate investment and do little for the environment
Environment

Mobilizing private capital for climate-driven growth

No Result
View All Result

Recent Posts

  • AI Has Entered the Boardroom. Who’s Overseeing It?
  • ‘Grand Theft Auto VI’ could be the biggest entertainment launch in history
  • Nvidia shares rally following earnings beat
  • Target reports its strongest sales growth in five years
  • Trump arrives in China for historic Xi, Putin meeting

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.